|

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

RECRUITINGSponsored by Cheng-Hsin General Hospital
Actively Recruiting
SponsorCheng-Hsin General Hospital
Started2023-01-01
Est. completion2025-12-23
Eligibility
Age20 Years – 90 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06006819

Summary

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.

Eligibility

Age: 20 Years – 90 YearsHealthy volunteers accepted
Inclusion Criteria:

* hospitalized for acute heart failure

Exclusion Criteria:

* initial serum NT-proBNP level \<300ng/ml, pregnancy, amputated, and end-stage renal disease under regular dialysis

Conditions4

Acute Heart FailureBiomarkerChronic Kidney DiseasesHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.